Benylin Cough

Quick links

Choose a section

Quick links to important sections

Advertisements

Benylin Cough

Advertisements

Treatment option:

Advertisements

Overview of Benylin Cough

Quick Facts

Property Description
Active Ingredients Diphenhydramine, Ammonium Chloride, Sodium Citrate, Menthol
Form Oral solution / Syrup
Pharmacological Class Multifunctional Cough and Cold Preparation
Common Use Symptomatic relief of cough and associated chest congestion
Origin Combination of synthetic and naturally derived components

The Identity and Classification of Benylin Cough

Benylin Cough is defined as a well-established Over-The-Counter (OTC) combination drug offered in the form of an oral solution or syrup. This preparation is classified within the domain of multifunctional cough and cold preparations, specifically formulated for oral intake to manage varied respiratory symptoms. Its identity as a combination product is intended for addressing the complexity of cough presentations, including both dry and productive forms, which differentiates it from single-agent formulations that target only one type of cough.

Core Composition: The Active Ingredients in Benylin Cough

The chemical foundation of this medicine is built upon the co-presence of four primary entities. The formulation includes Diphenhydramine Hydrochloride, a first-generation antihistamine that also functions as an antitussive, alongside the expectorant compound Ammonium Chloride and the mucolytic agent Sodium Citrate. Diphenhydramine is used to relieve common allergy symptoms and cough. The formulation includes the local soothing agent Menthol, which provides a characteristic cooling property. This blend of active agents is utilized for integrated symptom management.

General Purpose: What Benylin Cough is Formulated to Do

The general therapeutic purpose of Benylin Cough is to provide comprehensive symptomatic relief by addressing both neurological and physical aspects of coughing. The formulation aims to calm the cough reflex through the central action of Diphenhydramine while simultaneously tackling the presence of congestion. The expectorant and mucolytic components work to thin and loosen heavy bronchial secretions, facilitating the effective clearance of mucus and promoting easier, more comfortable respiration. The use of multiple agents is designed to provide broader efficacy against cough complexity by addressing different mechanisms concurrently for symptomatic relief.

Regulatory References

  1. Diphenhydramine Drug Information - NIH
Advertisements

What side effects are possible with Benylin Cough?

Possible Side Effects and Safety Information

The official safety profile for Benylin Cough is structured around the actions of its components, primarily the first-generation antihistamine, Diphenhydramine. Adverse reactions are documented according to regulatory frequency classifications and System-Organ Classes.


Frequency-Classified Adverse Reactions

The most commonly experienced effect documented in regulatory sources is somnolence (drowsiness or sedation), which is classified as very common. Other effects classified as common include dizziness, headache, dry mouth, nausea, vomiting, and urinary retention. Rare, but clinically significant adverse reactions include convulsions/seizures, certain blood disorders (such as agranulocytosis), and severe hypersensitivity reactions.

System-Organ Classes Affected

Adverse effects are categorized by the body system involved. Primary classifications include Nervous System Disorders (e.g., sedation, dizziness, headache), Gastrointestinal Disorders (e.g., dry mouth, constipation), and Renal and Urinary Disorders (e.g., urinary retention). Effects on the Cardiac and Vascular Systems (e.g., hypotension, tachycardia) and the Blood and Lymphatic System are also officially noted.


Population-Specific Safety Considerations

Regulatory documents include specific safety constraints for certain populations. The product is officially contraindicated in severe hepatic impairment or severe renal impairment due to the presence of Ammonium Chloride. Older adults are noted to be more susceptible to side effects like dizziness and confusion. For the pediatric population, there is an explicit caution regarding paradoxical excitation rather than sedation, and use is contraindicated in neonates and premature infants.

Advertisements

Overdose and Emergency Response

Overdose: When to Seek Help

The official overdose profile for combination cough products like Benylin Cough is determined by the toxicity of its active components, typically including Dextromethorphan and Diphenhydramine. Ingestion of amounts beyond the labeled dose can lead to a range of central nervous system (CNS), cardiovascular, and anticholinergic effects.

Documented Overdose Presentations

Physiological System Manifestations Described in Regulatory Documents
CNS Effects Drowsiness, lethargy, nystagmus (involuntary eye movement), confusion, hallucinations, agitation, and seizures. Severe cases may result in coma.
Cardiovascular Rapid heartbeat (tachycardia), high or low blood pressure.
Respiratory Difficulty breathing, shallow or slow breathing, or no breathing (especially in young children).
Anticholinergic Dry mouth, blurred vision, enlarged pupils, and difficulty urinating.

Required Emergency Actions

Immediate medical help must be sought right away if an overdose is suspected or if the person exhibits any severe symptoms. According to regulatory instructions, emergency services (such as 911) should be called if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. The treatment for overdose is primarily supportive, with emergency measures including monitoring vital signs, managing convulsions (e.g., with benzodiazepines), and providing respiratory support.

Advertisements

Therapeutic Uses of Benylin Cough

This preparation is applied across therapeutic domains where additional symptomatic support is needed, primarily focusing on conditions associated with the common cold, seasonal irritations, and upper respiratory tract symptoms. It is commonly used to help with symptoms related to inflammatory or irritative states, relevant for easing both the irritative dry cough and the productive cough that involves the buildup of heavy mucus and phlegm. The preparation assists in managing symptom clusters that may appear suddenly, such as bothersome nocturnal coughing and chest tightness.

Supportive Management of Cough and Congestion Symptoms

This medication is relevant for easing acute respiratory symptoms associated with conditions characterized by periods of heightened symptoms, including the common cold and seasonal allergies. It is applied to address symptoms that interfere with daily comfort, such as the persistent urge to cough, chest congestion, and throat irritation. The primary focus is to contribute to easing the overall symptom load and may assist with managing symptoms that create noticeable physiological strain.

“The preparation helps patients cope more steadily with difficult episodes by easing distress associated with persistent cough and congestion.”

Addressing Symptoms that Interfere with Comfort and Rest

The preparation is relevant in settings marked by heightened patient distress, offering short-term symptomatic support when acute manifestations interfere with rest. This is relevant when supportive symptom management is utilized, as it may contribute to maintaining functional stability and supports patients during difficult episodes by easing distress associated with nighttime symptoms.


Quick Fact: Relief for Cough and Congestion Symptom Type Therapeutic Focus
Cough Helps with both dry (irritative) and productive coughs
Congestion Helps with chest tightness and symptoms related to the buildup of mucus
Discomfort Supports comfort during nocturnal and acute symptom phases

Regulatory References

  1. NIH MedlinePlus overview of one active component
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Benylin Cough?

The population eligibility for Benylin Cough (Diphenhydramine formulation) is strictly defined by regulatory authorities based on age, health status, and concurrent treatments. This information is derived solely from official product labeling.


Official Eligibility Constraints

Classification Population/Condition Regulatory Status
Contraindicated Children under 12 years of age Prohibited
Contraindicated Known hypersensitivity to any ingredient Prohibited
Contraindicated Patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping Prohibited
Contraindicated Breastfeeding mothers (Lactation) Prohibited
Contraindicated Acute asthmatic attacks Prohibited
Caution Required Moderate to severe hepatic or renal dysfunction Use under professional guidance
Caution Required Glaucoma, symptomatic prostatic hypertrophy, or urinary retention Use with caution
Use Not Established Pregnancy Consult a professional

Official regulations permit use by Adults and Children aged 12 years and over under standard conditions. Caution is required for the elderly, who may be more susceptible to the product's sedative effects. The medicine must not be used concurrently with any other product containing diphenhydramine.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Regulatory information documents several interaction patterns for the active ingredients in this medicine, primarily Diphenhydramine and Ammonium Chloride.


Official Regulatory Restrictions

Classification Restriction and Outcome
Contraindicated Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited. A 14-day washout period must elapse after discontinuing an MAOI before this medicine can be taken, due to the risk of intensifying anticholinergic effects.
Pharmacodynamic Risk The consumption of Alcohol or co-administration with other Central Nervous System (CNS) depressants (including sedatives and opioid analgesics) is officially documented to result in additive effects, leading to enhanced sedation.

Pharmacokinetic Interaction Patterns

The medicine's ingredients are formally involved in two types of pharmacokinetic interaction:

  • Metabolic Inhibition: Diphenhydramine is identified as an inhibitor of the CYP2D6 enzyme. This can lead to an officially documented increase in the plasma concentration (exposure) of other co-administered medicines that are metabolized by that enzyme (e.g., certain beta-blockers and antidepressants).
  • Clearance Modification: The presence of Ammonium Chloride can alter urinary acidity, which is documented to decrease the systemic levels of certain basic drugs, such as amphetamines, by increasing their renal clearance. Co-administration with other medicines that have significant anticholinergic activity may also potentiate these effects.
Advertisements

Mechanism of Action

Central Modulation of the Cough Reflex Arc

This antitussive mechanism is mediated by Diphenhydramine, which acts as an antagonist on central histamine H1 receptors in the brainstem. By disrupting histaminergic signaling within the medullary cough center, this interaction increases the neuronal activity required to initiate the cough motor response.


Peripheral Secretion Fluidization and Clearance

Ammonium Chloride and Sodium Citrate support mucociliary clearance through peripheral actions that target the fluid content and viscosity of the bronchial secretions. This process increases the volume and reduces the thickness of the airway mucus, resulting in thinner, less viscous bronchial secretions that facilitate mucociliary clearance.


Coordinated Multi-Target Mechanism

Physiological modulation results from the coordination between central and peripheral components. Central suppression reduces the neurological drive, while Menthol modulates sensory input through TRPM8 channel activation. The secretolytic agents concurrently modify the physical characteristics of the airway secretions, enabling the mechanism to target both the central reflex arc and the physico-chemical properties of the mucus matrix simultaneously.

Advertisements

Dosage and Administration Information

How to Use Benylin Cough: Administration Guidelines

Benylin Cough oral solution (Diphenhydramine-containing formulation) is administered according to specific principles. The medicine is strictly for oral intake, differentiating its usage from other administration routes. The established regimen dictates that the solution is taken as required for short-term symptomatic use, establishing a pattern of intermittent use rather than a long-term maintenance course.


Official Dosing and Frequency

The administration of the oral solution is governed by specific volumetric and temporal constraints. For adults and adolescents 12 years and over, the standard single dose is 10 ml of the syrup. To ensure accuracy, the dose must be measured using a 5 ml spoon or an appropriate measuring device. The frequency of administration is limited to a maximum of four doses within a 24-hour period. A minimum interval of four hours is required between successive doses, and the total intake must not exceed the 40 ml maximum daily dose.


Population-Specific Use Rules

Specific rules apply regarding age-group administration. The use of this preparation is contraindicated for children under the age of 12 years. For older adults, the dosing regimen is the same as that for the general adult population. In cases of moderate to severe renal impairment, the dosage interval is extended to ensure proper administration conditions are maintained.

This framework of instructions defines the standardized procedure for using the medicine, following established administration requirements.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Benylin Cough


Evidence for use in Dry or Unproductive Cough

Research was observed in short-term randomized trials to explore active ingredients like dextromethorphan. These studies were studied for use in conditions characterized by fluctuating or episodic manifestations to monitor outcomes related to physical discomfort, specifically the frequency and intensity of a dry or tickly cough. Studies monitored patient-reported outcomes describing perceived discomfort and noted how symptoms evolved in the groups receiving the active ingredient versus placebo. Research exploring short-term symptom changes generally features follow-up durations that were limited, and data for certain groups remain insufficient.


Evidence for use in Productive or Chesty Cough (Where applicable)

Other formulations containing different active ingredients, such as guaifenesin, were studied for use in conditions associated with acute or disruptive episodes where mucus clearance is a factor. These trials research examined how the ingredients may affect outcomes related to systemic or functional imbalance and outcomes reflecting daily functioning or activity level when cough is associated with chest congestion. Studies reported how symptoms evolved in the observed populations, where patient-reported experiences described some changes in the perception of chest heaviness or the ease of clearing secretions. The overall evidence remains limited concerning the broader impact of this ingredient on the condition marked by functional limitations over extended periods.


Long-term Studies and Follow-up

Most available research relevant to the active ingredients in Benylin Cough was observed in trials relevant in trials assessing short-term or episodic symptom patterns. These studies are generally designed to monitor physiological strain or stress and symptomatic changes over a few days or weeks. Because cough from common, temporary issues is naturally short-lived, there is limited information for long-term outcomes from extended follow-up trials. Research has generally focused on episodic symptom patterns, and current data was observed in some studies with follow-up durations that were limited.


What is Still Uncertain About Benylin Cough Research

A significant research limitation is that the follow-up durations were limited across most trials, meaning long-term effects are not fully established. Comparative evidence is lacking to fully determine how the active ingredients compare against all other available products or non-medicinal approaches. Evidence quality varies across studies, and the findings were mixed when assessing the magnitude of the reported changes in patient-reported outcomes describing perceived discomfort. The research provides context but not individual predictions about changes in symptoms, and certainty remains low in areas where sample sizes were modest.

Key Studies & References

  1. Guaifenesin. Monograph. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Benylin Cough (FAQ)


Q: What is the main difference in purpose between Benylin for 'Dry Coughs' and Benylin for 'Chesty Coughs'?

Official product information shows that different Benylin cough products are formulated with different active ingredients to target specific symptoms. Products indicated for a dry or irritating cough primarily contain a cough suppressant like Dextromethorphan. Products for a chesty cough and congestion contain ingredients such as Guaifenesin or Ammonium Chloride, which are described as working to loosen phlegm and thin secretions.


Q: Does Benylin Cough only work to stop a cough, or does it have other effects?

The medicine is primarily indicated for the temporary relief of cough and associated congestive symptoms. The Diphenhydramine component, found in some formulas, is a first-generation antihistamine which official information indicates may be associated with effects such as sedation and anticholinergic activity, in addition to its cough-suppressing action. Other ingredients may also help modify bronchial secretions.


Q: Is Benylin Cough considered an antitussive, an expectorant, or both?

The classification depends on the specific formula. Products containing ingredients like Dextromethorphan are primarily antitussive (cough suppressant). Products containing ingredients like Guaifenesin are expectorants, used to help loosen mucus. Certain formulas may contain multiple active ingredients that are described as targeting both antitussive and expectorant functions.


Q: Is it true that different Benylin products contain different active ingredients?

Yes, regulatory documents for the Benylin brand confirm that different versions are available, each containing unique combinations of active substances. These may include Dextromethorphan, Diphenhydramine, Guaifenesin, and others, depending on the intended use and specific country of sale.


Q: How quickly can a person expect Benylin Cough to start working?

Official information for Dextromethorphan-containing formulas indicates that the cough-suppressing effect typically begins within 15 to 30 minutes. For formulas containing Diphenhydramine, official dosing guidelines establish a minimum interval between doses of four hours, which is related to the drug's duration of activity.


Q: What should a person do if they experience restlessness or difficulty sleeping after taking Benylin Cough?

While drowsiness is a common side effect of Diphenhydramine-containing products, paradoxical stimulation (including restlessness, excitement, or insomnia) is also a known effect, especially in children and occasionally in adults. If this or other unexpected symptoms occur, regulatory information indicates that these should be brought to the attention of a healthcare professional.


Q: Do any Benylin Cough ingredients carry a risk of dependence or misuse?

Official regulatory warnings state that for all patients, prolonged use of certain Benylin products may carry a risk of drug dependence (addiction), even when taken at therapeutic doses. These risks are noted to be increased in individuals with a history of substance misuse disorder.


Q: Can Benylin Cough products be used safely during pregnancy?

Official product information indicates that the use of these products during pregnancy is generally not advised unless a physician determines the potential benefit outweighs the possible risks to the fetus. It is known that Diphenhydramine, an ingredient in some products, crosses the placenta.


Q: Is there any information available regarding the use of Benylin Cough while breastfeeding?

Use of the medicine while breastfeeding is generally not recommended. Regulatory information confirms that ingredients like Diphenhydramine are excreted into human breast milk, and patients are directed to consult with a healthcare professional to review the risks.


Q: Should someone with chronic conditions like asthma or COPD avoid using Benylin Cough?

Official precautions state that the product is generally contraindicated (should not be used) for a persistent or chronic cough, such as those associated with chronic bronchitis or emphysema, or acute or chronic asthma. The use of the product in these conditions is generally subject to the advice of a physician.


Q: What are the considerations for someone with high blood pressure or heart disease when taking certain Benylin products?

Regulatory documents indicate that patients with pre-existing heart conditions should review the product with a healthcare provider prior to use. While not a direct contraindication for all types, side effects like hypotension (low blood pressure) and tachycardia (increased heart rate) are noted adverse reactions.


Q: Can Benylin Cough be used by people with diabetes, considering its sugar content?

Some Benylin products contain sweeteners such as glucose and sucrose (sugar) among their excipients. Official information notes that this sugar content is a consideration for patients with diabetes mellitus.


Q: What should be done if the cough persists for more than a few days after starting Benylin Cough?

Regulatory guidance suggests that if the cough is chronic or persists for more than five to seven days, a physician should be consulted. In addition, the official documents state that medical review is advised if the cough recurs or is accompanied by other symptoms such as a high fever or persistent headache.


Q: Is there a non-drowsy formulation of Benylin Cough available, and what is the difference in ingredients?

Yes, non-drowsy versions of Benylin cough products are available. These products typically exclude the sedating first-generation antihistamine Diphenhydramine, substituting it with ingredients that do not cause significant drowsiness, such as Dextromethorphan or Guaifenesin, often for daytime use.


Q: What is the source of the flavor or color in the syrup forms of Benylin Cough?

Regulatory documents list the non-medicinal ingredients (excipients) that provide the color and flavor. For example, some syrups contain Ponceau 4R (E124) red coloring, and specific flavorings are listed separately among the product components.


Q: What are the non-medicinal ingredients in the syrup that may be relevant to certain allergies or sensitivities?

Regulatory lists of excipients include components such as Ponceau 4R (E124) and Benzyl alcohol, which may cause allergic reactions in sensitive individuals. Official warnings list that patients with certain rare hereditary problems, such as fructose intolerance, may need to use caution due to the sugar content.


Q: Does Benylin Cough address a cough caused by allergies or post-nasal drip?

The active ingredient Diphenhydramine, present in some formulations, is a first-generation antihistamine. While antihistamines can help manage allergy symptoms, the product’s official indication is for the relief of cough and associated congestive symptoms. The precise cause of a cough is best determined by a healthcare provider.


Q: Is there a risk of developing tolerance to the effects of Benylin Cough with repeated use?

The official product information for some formulas warns that prolonged use may lead to drug dependence, or addiction, and the medicine is intended for short-term symptomatic relief. The official warning focuses on the risk of drug dependence, and tolerance is often considered a related aspect of prolonged use.


Q: How should a person determine which specific Benylin Cough product is intended for their type of cough?

Regulatory information advises patients to review the product label to ensure the formula’s intended use (e.g., 'dry and irritating' or 'chesty and congested') aligns with their current symptoms. Different product types are explicitly formulated for different cough patterns.


Q: Are there specific warnings for individuals with glaucoma or difficulty urinating when using Benylin products?

Yes, due to the anticholinergic properties of Diphenhydramine, regulatory warnings state that these products are generally contraindicated in individuals with susceptibility to angle-closure glaucoma and conditions like symptomatic prostatic hypertrophy or urinary retention. Official documents indicate that these conditions necessitate review with a physician prior to use.


Q: Is the presence of alcohol in some Benylin Cough formulas a cause for concern?

Some Benylin products contain small amounts of ethanol (alcohol) as an excipient. The official regulatory documents state the exact amount per dose and clarify that this small quantity is not expected to have any noticeable effects on the user.


Q: Does Benylin Cough have an expiry date, and can expired product be used?

Yes, Benylin products have a defined shelf-life, typically around two years for the unopened product, as noted in regulatory sources. Official guidance directs that medicines past their expiry date should be properly disposed of and not administered.

Advertisements

How should Benylin Cough be stored and disposed of?

Storage and Disposal of Benylin Cough Syrup

Official regulatory labeling defines specific conditions for storing and disposing of Benylin Cough syrup to maintain stability and ensure safety.


Mandatory Storage Conditions

Temperature and Container: The product must be stored in its original container at a temperature not exceeding 25 C or 30 C, depending on the formulation. The container must be kept tightly closed to protect the contents from moisture.

Child Safety: All formulations must be stored out of the sight and reach of children.

Stability and Disposal

In-Use Stability: After opening, the syrup has a defined shelf-life; for example, some Chesty Cough formulations must be discarded after 4 months, regardless of remaining product.

Disposal: Unused or expired medicine must not be disposed of via wastewater or household waste. Users are required to ask a pharmacist for guidance on proper disposal to ensure compliance with environmental protection measures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Benylin Cough found in:

A-Z Index: